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A Ab bs st tr ra ac ct t
HNPCC (Lynch syndrome) is the most common form of hereditary colorectal cancer (CRC), wherein it accounts for
between 2-7 percent of the total CRC burden. When considering the large number of extracolonic cancers integral
to the syndrome, namely carcinoma of the endometrium, ovary, stomach, hepatobiliary system, pancreas, small
bowel, brain tumors, and upper uroepithelial tract, these estimates of its frequency are likely to be conservative. Tthe
diagnosis is based upon its natural history in concert with a comprehensive cancer family history inclusive of all
anatomic sites. In order for surveillance and management to be effective and, indeed, lifesaving, among these high-
-risk patients, the linchpin to cancer control would be the physician, who must be knowledgeable about hereditary
cancer syndromes, their molecular and medical genetics, genetic counseling, and, most importantly, the natural
history of the disorders, so that the entirety of this knowledge can be melded to highly-targeted management.
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I In nt tr ro od du uc ct ti io on n
The annual worldwide incidence of colorectal
cancer  (CRC)  is  approximately  944,717  (males:
498,754;  females:  445,963)  and  its  worldwide
mortality incidence is approximately 492,411 (males:
254,816; females: 237,595). In Poland, the annual
incidence of CRC is approximately 13,327 (males:
6,916;  females:  6,411)  and  its  mortality  is
approximately 7,877 (males: 3,883; females: 3,994)
[1]. The lifetime CRC risk in the general population is
about 5-6% [2], but there is considerable racial and
ethnic variation. For example, the lifetime CRC risk for
Ashkenazi Jews ranges between 9% and 15% [3]. 
The familial clustering of two or more first - and/or
second-degree  relatives  with  CRC  constitutes
approximately 20% of the total CRC burden, while a
Mendelian inherited (monogenic) etiology for CRC
accounts for approximately 5-10% of the total CRC
burden. Among hereditary CRC-prone syndromes with
multiple colonic polyps (adenomatous, juvenile, Peutz-
Jeghers,  mixed  [hamartomatous,  hyperplastic,
adenomatous]),  the  best  known,  namely  familial
adenomatous polyposis (FAP), accounts for less than
1% of the total CRC burden, while the other syndromes
in this group combine to account for another fraction
of a percent of the total CRC incidence [4, 5]. In
contrast to those hereditary CRC disorders, hereditary
nonpolyposis colorectal cancer (HNPCC), also known
as Lynch syndrome, represents 2-7% of the total CRC
burden [6]. Herein, the Lynch syndrome is the most
common form of hereditary CRC.
Our purpose is to review the history, clinical,
pathologic, and molecular genetic features of HNPCC
(Lynch syndrome). Special attention will be given to its
differential diagnosis and molecular genetics, in
concert  with  state-of-the-art  surveillance  and
management recommendations.H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2003; 1(1) 8
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I Im mp po or rt ta an nt t   C Cl li in ni ic ca al l   C Co on ns si id de er ra at ti io on ns s: :   
F Fa am mi il ly y   H Hi is st to or ry y
Soliciting cancer family history information is crucial
to diagnosing a hereditary cancer syndrome and the data
should be recorded in every cancer-affected patient’s
medical  chart.  Given  the  variable  genotypic  and
phenotypic features of hereditary CRC, inclusive of
HNPCC, medical and pathology confirmation on cancer
of all anatomic sites should be obtained whenever
possible. It is necessary to record the age of each cancer
onset, evaluate the pattern of multiple primary cancer
occurrences,  and  note  generation  to  generation
transmission  of  cancers  such  as  CRC  and
endometrium/ovarian carcinoma in HNPCC. Recognizing
the possible reduced penetrance that may occur in
cancer-prone lineages will be extremely important. 
Ideally, genealogic and medical information should
include three generations, i.e., the proband, parents,
aunts and uncles, both sets of grandparents, and progeny
(Figure 1). When evaluating the patient’s parents, aunts
and uncles, and both sets of grandparents, we are
dealing with older individuals who, more than likely, will
have passed through the cancer risk age and thereby will
be genetically informative [6]. When collecting the cancer
family history, as well as when interpreting the pedigree,
an awareness of the cardinal features of hereditary cancer,
as shown in Table 1, is extremely valuable. 
H Hi is st to or ry y   o of f   H HN NP PC CC C
The history of what is known as HNPCC dates to
an observation of Aldred Warthin, pathologist at the
University of Michigan School of Medicine [7]. He
became deeply moved when his seamstress, in 1895,
told him that she would likely die of cancer of the
colon, stomach, or her female organs, because of the
enormous proclivity to these cancers in her family
(unfortunately, just as she had told Warthin, she died
at a young age of metastatic endometrial carcinoma).
Warthin listened intently, developed her pedigree, and
along  with  other  similar  cancer  prone  families
published his work in 1913 [8]. Warthin updated the
family in 1925 [9]. The seamstress’s family has since
been known as Family G. 
T Ta ab bl le e   1 1. .   Cardinal features of hereditary cancer
C Ca ar rd di in na al l   F Fe ea at tu ur re es s   o of f   H He er re ed di it ta ar ry y   C Ca an nc ce er r
* Earlier average age of cancer onset than in the general population; 
for example, the average age of CRC onset in HNPCC is ≈45 years, 
while the average age of onset in sporadic CRC is ≈63 years [6].
* A pattern of primary cancers segregating within the pedigree [6, 19].
* Possible survival differences [71, 79-81]. 
* Occasional pathology distinguishing features [82, 83]. 
* The sine qua non, the identification of a germline mutation 
segregating with syndrome-affected individuals in the family [45].
F Fi ig g. .   1 1. . Diagram reflecting the minimum information necessary to compile a cancer family history for hereditary cancer syndrome diagnosis.
(Reprinted by permission from Lynch et al. Surv Dig Dis 1984; 2: 244-60)
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Lynch et al. [10] described the natural history and
genetics of two large Midwestern kindreds (Families N
and M) in 1966. The clinical genetic features in these
families were similar to those of Family G [10]. Dr. A.
James French, Warthin’s successor as chairman of
pathology at the University of Michigan, heard about
Lynch’s research on Families N and M, [10] and
recalled that Warthin, his predecessor, had discovered
a similar family (Family G) in 1895. Lynch was then
invited by French to take custody of all the detailed
documents  and  pathology  specimens  which  the
meticulous Warthin had investigated, catalogued, and
published over a span of more than 30 years [8, 9].
Family G was then updated and published in 1971
[11]. This material is discussed in a more detailed
review of the history of HNPCC [12]. Through the use
of conversion technology, [13] an MSH2 mutation was
identified in Family G in the year 2000. 
W Wh ha at t   i is s   H HN NP PC CC C   ( (L Ly yn nc ch h   S Sy yn nd dr ro om me e) )? ?
HNPCC is the most common autosomal dominantly
inherited  cancer  syndrome  that  predisposes  to
colorectal  cancer  (CRC)  [5,  6].  Estimates  of  its
frequency range from two to as much as seven percent
of the total CRC burden [6, 14-16]. CRC occurs at an
early age (≈44 years), with right-sided predominance
(≈70% proximal to the splenic flexure), [5, 6, 17] and
a  significant  occurrence  of  synchronous  and
metachronous lesions [6, 18]. There is an excess of
extracolonic cancers, the most common of which is
carcinoma of the endometrium, followed by cancers
of the ovary, stomach (particularly in Asian countries
such as Japan and Korea), small bowel, pancreas,
hepatobiliary  tract,  brain,  and  transitional  cell
carcinoma of the upper uro-epithelial tract (Figure 2)
[19,  20].  Some  families  also  have  phenotypic
manifestations such as sebaceous adenomas and/or
sebaceous carcinomas consistent with the Muir-Torre
syndrome  (Figure  3)  [6,  21-27].  Profuse  colonic
adenomas  consonant  with  classical  familial
adenomatous polyposis (FAP) and its attenuated variant
(AFAP) must be excluded in the medical evaluation of
patients at high risk for HNPCC [5, 6].
The Amsterdam criteria [28] and the more recent
Amsterdam II criteria, [29] as well as the Bethesda [30]
(Table 3) or European experts’ [31, 32] guidelines are
clinically useful in the diagnosis of HNPCC. However
useful these criteria might be for assessing the diagnosis
of HNPCC, there will be clinical situations wherein the
family may be uninformative for their application, such
as it often occurs in very small families. Additional
factors which could obfuscate an HNPCC syndrome
diagnosis in a patient/family and pose significant
confounders for interpretation of the family history,
include: a) false paternity; b) incomplete family history;
c) reduced penetrance of the deleterious mutation in
a key, otherwise informative individual such as the
parent of an affected; d) loss or destruction of medical
and pathology documents; e) poor cooperation; f) a
situation where an otherwise informative individual has
been adopted; or g) the death of one or more key
family members early in life due to causes other than
cancer. Therefore, many of the pertinent diagnostic
features of HNPCC may not be present. However, in
the face of these limitations, the cancer phenotype,
particularly when severe, in a single family member, as
evidenced in the family report discussed subsequently,
may elucidate the HNPCC diagnosis. 
C Co ol lo on ni ic c   A Ad de en no om ma as s   a an nd d   H HN NP PC CC C
A newly described feature of the Lynch syndrome
phenotype pertains to the adenoma distribution in the
colon. Specifically, Rijcken et al. [33] reasoned that in
HNPCC  the  CRCs  are  believed  to  arise  from
adenomas in the proximal colon, since the CRCs occur
predominantly in that anatomic area. They, therefore,
investigated whether this proximal CRC predominance
is due to a right-sided predominance of adenomas. In
addition, they pursued whether there was a difference
in rates of transformation of adenomas to cancer
T Ta ab bl le e   2 2. .   Recommended colonic and extra-colonic surveillance in
HNPCC
S Si it te e S Sc cr re ee en ni in ng g
Colon Annual full colonoscopy initiated between 
ages 20 and 25
Endometrium Annual transvaginal ultrasound and
Pelvic examination beginning at age 30; 
Endometrial aspiration for pathology assessment  
Ovary Transvaginal ovarian ultrasound 
and CA-125 analysis (serious limitations
due to reduced sensitivity and specificity)
Stomach Consider upper endoscopy in natives 
of Korea or Japan and/or in families with 
an excess of stomach cancer
Upper  Urine samples for rbc and cytology 
uro-epithelial  in concert with ultrasound
tract
Other sites Consider in families with an excess of cancer
of a particular extra-colonic site H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2003; 1(1) 10
relevant to differences between distal and proximal
colon location of the adenomas. They concluded that
adenomas in HNPCC are located mainly in the
proximal colon where they show progression to high-
grade dysplasia which is more common in the proximal
as opposed to distal HNPCC adenomas. These polyps
also showed a faster malignant transformation rate
from early adenoma to cancer in the proximal colon.
They  concluded  that,  “...MMR  gene  malfunction
probably does not initiate adenoma development but
is present at a very early stage of tumorigenesis and
heralds the development of high grade dysplasia“ [33].
Colonic adenomas, therefore, appear to differ in
HNPCC  when  compared  to  their  sporadic
counterparts, wherein families with HNPCC show an
earlier age at colonic adenoma onset coupled with a
high degree of dysplasia. There appears to be a similar
proximal localization of adenomas and carcinomas in
HNPCC, thereby suggesting an increased risk of
cancer in all HNPCC adenomas [34, 35]. There also
appears to be a faster progression of adenomas to
CRC when compared to non-HNPCC families, who
have a later onset and lower risk of cancer from
proximal adenomas [33-35].
P Pr ro ob bl le em m   C Cl li in ni ic ca al l   E Ex xa am mp pl le es s   
o of f   E Ex xi is st ti in ng g   H HN NP PC CC C   D Di ia ag gn no os st ti ic c   C Cr ri it te er ri ia a
Cao et al. [36] describe a 62-year-old patient with
duodenal  adenocarcinoma  who  had  previously
undergone a subtotal colectomy for CRC. He had had
only  ten  adenomatous  colon  polyps  when  he
underwent a subtotal colectomy for cancer. Therefore,
classic FAP was tentatively excluded. His brother had
rectal cancer at age 69, his mother had CRC at age
75, and one maternal cousin had colon cancer at age
42. The extreme rarity of duodenal adenocarcinoma
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F Fi ig g. .   2 2. .   Updated pedigree of an extended HNPCC family showing early age at cancer onset, occurrence of multiple primary syndrome
cancers, at several anatomic sites. (Updated with permission from Lynch et al. Am J Gastroenterol 1988; 83: 741-7)
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in the general population, coupled with the patient’s
family history of CRC, particularly late age of onset,
caused attenuated familial adenomatous polyposis
(AFAP) to be suspected [37]. 
During the course of this family study, it was only
after the proband’s 32-year-old son manifested rectal
carcinoma that the family was found to fulfill the
Amsterdam criteria for HNPCC. However, AFAP still
could not be excluded. Germline testing of the
proband was negative for the APC mutation, which
suggested that AFAP was highly unlikely, but could
not be completely excluded, since a small subset of
FAP families will not harbor the APC mutation.
However,  microsatellite  instability  (MSI)  was
subsequently identified in the proband’s adenomas
and cancer tissues. Therefore, the fulfillment of the
Amsterdam criteria, with exclusion of FAP and AFAP ,
in concert with MSI positivity, led to confidence in the
diagnosis of HNPCC in the family. The phenotypic
and genotypic differences among FAP , AFAP , and
HNPCC must always be considered in the differential
diagnosis of HNPCC. 
G Ge en no ot ty yp pe e- -P Ph he en no ot ty yp pe e   H He et te er ro og ge en ne ei it ty y
HNPCC, not unlike other autosomal dominantly
inherited disorders, is noteworthy for genotypic and
phenotypic heterogeneity [6, 38, 39]. MSH2 mutations
possibly predispose to the more severe phenotypic
cancer phenomenon in HNPCC. For example, Vasen
et al. [40] studied 138 families with HNPCC wherein
mutations were identified in 79 of those families (34
with MLH1, 40 with MSH2, 5 with MSH6). They found
that the lifetime risk for developing cancer at any
anatomic  site  was  significantly  higher  for  MSH2
mutation carriers as opposed to MLH1 mutation
carriers (p<0.01). With respect to specific anatomic
sites, findings disclosed that, “...The risk of developing
colorectal or endometrial cancer was higher in MSH2
mutation carriers than in MLH1 mutation carriers, but
the  difference  was  not  significant  (p=0.13  and
p=0.057, respectively). MSH2 mutation carriers were
found to have a significantly higher risk of developing
cancer of the urinary tract (p <0.05). The risk of
developing cancer of the ovaries, stomach and brain
was also higher in the MSH2 mutation carriers than in
the MLH1 mutation carriers, but the difference was not
statistically significant.“ 
T Th he e   F Fa am mi il ly y   I In nf fo or rm ma at ti io on n   S Se er rv vi ic ce e   ( (F FI IS S) )   
Genetic counseling must impart to the patient and
his/her extended family important details about their
genetic risk, based on the natural history of the
hereditary cancer syndrome, their surveillance and
management options, and the availability of genetic
testing (Table 2) [41]. Education about these issues can
be effectively provided to as many members of a
hereditary cancer-prone family as elect to attend a
group meeting [41]. We call such a meeting a family
information service (FIS). 
The FIS provides family members with a unique
opportunity to empathize with each other about the
impact of the “family disease“ and, importantly, they
can discuss their coping mechanisms with each other.
They often appear to gain emotional strength through
“group therapy“ [42]. Often patients have stated that
the FIS was the first time that a physician had told them
what could “kill them“, and, importantly, covered the
advantages and disadvantages of germline mutation
testing, and provided screening and management
recommendations (Table 2). 
T Ta ab bl le e   3 3. .   Bethesda Guidelines [30]
B Be et th he es sd da a   G Gu ui id de el li in ne es s   [ [3 30 0] ]
1. Subjects with cancer in families that fulfill Amsterdam Criteria. 
2. Subjects with two HNPCC-related cancers, including synchronous and metachronous CRCs or associated extracolonic cancers.
3. Subjects with CRC and a first-degree relative with CRC and/or HNPCC-related extracolonic cancer and/or colorectal adenoma; 
one of the cancers diagnosed at age <45 years and the adenoma diagnosed at age <40 years.
4. Subjects with CRC or endometrial cancer diagnosed at age <45 years.
5. Subjects with right-sided CRC with an undifferentiated pattern (solid/cribiform) on histopathology diagnosed at age <45 years.
6. Subjects with signet ring cell type CRC diagnosed at age <45 years.
7. Subjects with adenomas diagnosed at age <40 years.H
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F Fi ig g. .   3 3. .   Updated pedigree of a large HNPCC family reflecting the natural history features of the syndrome and, in addition, the Muir-Torre cutaneous phenotype. (Updated with permission from
Lynch et al. Br J Dermatol 1985; 113: 295-301)
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Once the relevant germ line mutation has been
identified through testing of a consenting syndrome
cancer-affected family member, others are counseled
and, when consenting, offered testing. When results of
this  testing  become  available,  a  second  FIS  is
scheduled. The natural history of the disorder, the pros
and cons of knowing one’s DNA mutation status, and
cancer  screening  and  management  information
(inclusive  of  prophylactic  surgical  options),  are
discussed once again [43, 44]. Mutation test results
are then revealed on a one-to-one basis, once signed
consent has been given.
G Ge en ne et ti ic c   C Co ou un ns se el li in ng g
Genetic counseling must take place both prior to
the collection of DNA and at the time of disclosure of
the results. Ambiguous genetic test results (missense
mutations) pose a diagnostic problem in that they
cannot unequivocally be used to exclude cancer risk
status. Specifically, one must consider a patient’s
position in the pedigree, whether or not a germline
mutation has been identified in other first- and/or
second-degree relatives of that patient and whether or
not any extra-cancer phenotypic manifestations such
as  sebaceous  adenomas  and/or  sebaceous
carcinomas consistent with the Muir-Torre syndrome
variant of HNPCC, might be identified. In short, one
cannot entirely exclude hereditary cancer susceptibility
based upon an ambiguous genetic test result [45]. 
When the diagnosis of hereditary CRC is confirmed,
one then ideally considers the proband’s high-risk
relatives and implements genetic counseling and DNA
testing in these consenting individuals, as well as
surveillance measures which need to be implemented
in accord with the disorder’s natural history in the interest
of reduction of cancer’s morbidity and mortality (Table
2). It is in this realm that consultation with a cancer
genetics center may complete this cancer prevention
cycle [6]. Although physicians’ knowledge about cancer
genetics is improving, several studies have shown the
need for a better understanding of this area [46-48].
I In nf fo or rm me ed d   C Co on ns se en nt t   
a an nd d   M Mo ol le ec cu ul la ar r   G Ge en ne et ti ic c   T Te es st ti in ng g
Prior  to  the  collection  of  peripheral  blood
lymphocytes for DNA, which will be used for germline
mutation testing, the patient must provide informed
consent. This is a process which involves the patient as
a knowledgeable adult participant, meaning that he
or she has been thoroughly educated about the
disorder and the implications of receipt of information
regarding the cancer phenotype and its penetrance
due to a cancer-causing germline mutation. The
significance of a negative finding when a mutation has
not been identified in the family must also be fully
explained. A true negative mutation result must be
based upon the identification of the mutation in the
family, including its segregation in syndrome cancer
affecteds (a true positive mutation). The short- as well
as long-term psychological and cancer (phenotype)
impact of such a mutation finding must then be
discussed [6, 41, 49]. 
Respect must be given to the patient’s autonomy as
well  as  self-determination  relevant  to  the  medical
decision-making process. The nature and purpose of the
DNA studies, risks and benefits of knowing the results, as
well as penalties such as the potential for insurance or
employment discrimination, coupled with the fact that the
outcome of testing will in no way guarantee success
through management, must be understood by the patient
(For a review, see Rex et al. [50]).
D DN NA A   T Te es st ti in ng g   S St tr ra at te eg gi ie es s: :   M MS SI I, ,   
I Im mm mu un no oh hi is st to oc ch he em mi is st tr ry y, ,   
a an nd d   M Mi is sm ma at tc ch h   R Re ep pa ai ir r   M Mu ut ta at ti io on n   T Te es st ti in ng g
The ultimate objective of DNA testing is to discern
who is at inordinately high risk for cancer by virtue of
manifesting  the  specific  cancer-causing  germline
mutation, thereby indicating the necessity of preventive
procedures or early treatment. 
M Mo ol le ec cu ul la ar r   G Ge en ne et ti ic cs s   o of f   L Ly yn nc ch h   S Sy yn nd dr ro om me e
Mutations in six different MMR genes have been
identified in HNPCC patients: MLH1, located on
chromosome 3p21; MSH2 on 2p16, MSH6 on 2p15;
PMS2 on 7p22; MLH3 on 14q24.3; and possibly
PMS1 [51], located on 7p22 [51-57]. However, only
40-60%  of  HNPCC  patients  harbor  identifiable
germline mutations, most common of which are MSH2
and MLH1 mutations [58]. Approximately 90% of the
identified HNPCC mutations involve MLH1 or MSH2,
while  mutations  in  the  MSH6 gene  account  for
approximately  10%.  MSH6 mutations  appear  to
predispose to an excess of endometrial cancer and a
deficit of CRC [39]. These findings therefore suggest
that other genes, including modifier genes, may be of
etiologic importance in HNPCC. The occurrence of
mutation  types  that  are  difficult  to  detect,
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explain the etiology of those 40-60% of HNPCC
families in which no known cancer-causative germline
mutations have to date been identified [6, 59]. The
mutation database maintained by the ICG-HNPCC
is an important source of first reference (www.nfdht.nl).
Molecular genetic testing of a genetically informative
affected  family  member  is  the  sine  qua  non for
establishing an unequivocal HNPCC diagnosis. This
can be partially facilitated by the finding of positivity of
microsatellite instability or loss of MMR gene protein
expression in a malignant colon tumor in the HNPCC
family setting [58]. Testing for a mismatch repair
germline mutation, when present, will be confirmatory
of HNPCC. In turn, family members who are negative
for the mutated MMR gene will not have to undergo
the rigorous screening which will be recommended for
those who are positive, and will revert to general
population screening recommendations. As mentioned,
a true negative DNA diagnosis can be established with
certainty only when the subject germline mutation has
been identified in an affected informative relative and,
ideally, when it has segregated in the family among
additional HNPCC affecteds. 
Exon by exon sequencing is the most sensitive
technique for the detection of germline mutations in
HNPCC using genomic DNA as the template for
analysis. However, cost and sensitivity limitations can
partially be overcome by RNA-based analysis [60].
Jakubowska et al. note that, “...primers specific for RT
[reverse transcription] of MLH1 and MSH2 are crucial
for increasing the sensitivity of cDNA analysis. DNA
sequencing  using  RNA  as  a  basis  for  template
construction may be a valuable and economical
alternative to genomic DNA sequencing“ [60].
In many cases, immunohistochemical analysis of
the MMR gene protein in the tumor can provide clues
as to which MMR gene is involved if staining for one
of the proteins is weak or absent [61, 62]. Wahlberg
et al. [63] studied 48 HNPCC families where a tumor
sample was available for the evaluation of the presence
of germline mutations in MSH2 and MLH1, for MSI,
and, whenever possible, expression of MSH2 and
MLH1 in tumors by immunohistochemistry (IHC).
Genomic DNA sequencing revealed 14 of the 48
families to harbor a germline mutation in either MSH2
or MLH1. Loss of expression of MSH2 was found in
four additional families, while one additional family
showed loss of expression of MLH1 but did not harbor
a germline mutation in MSH2 or MLH1 that could be
detected by DNA sequencing. MSI-H (MSI-High)
showed 100% sensitivity for identifying samples having
MSH2 or MLH1 mutations or loss of protein expression.
However, loss of MSH2 and MLH1 expression failed
to identify all samples showing germline mutations in
MSH2 or MLH1, since in five cases a mutant protein
product was expressed that would be detected by IHC.
The authors concluded that, “...a combination of the
Bethesda criteria for HNPCC and MSI-H phenotype
defined the smallest number of cases having all of the
germ-line MSH2 and MLH1 mutations that could be
detected by DNA sequencing“ [63].
Debniak et al. [64] evaluated the cost-effectiveness
of pedigree/clinical data, IHC, and MSI analysis. Cost
reduction of MLH1 and MSH2 germline mutation testing
in individuals at high risk for CRC is always an important
consideration. Herein, they evaluated 168 patients with
CRC which included 43 consecutive sporadic late-onset
and 25 consecutive likely HNPCC cases examined by
IHC and MSI. In the HNPCC suspect cases, 6 of 25
(24%) patients with constitutional mutations were
identified, while no germline mutations were found in
the sporadic late-onset subjects. Of keen interest was
the finding that, “...The lowest costs (880 Euro/mutation
detected) were achieved by performing pedigree/clinical
data (for exclusion of late-onset sporadic CRC) in
conjunction with IHC only. In this model, 1/6 (17%)
mutations were missed. Additional preselection by IHC
and MI [MSI] analyses before sequencing was required
to detect all mutations. In this approach, which seems
to be the most effective in the search for hMLH1 and
hMSH2 gene  mutation,  the  cost  was  1767
Euro/mutation detected.“
A As ss se es ss si in ng g   t th he e   P Pa at th ho og ge en ni ic ci it ty y   o of f   M Mu ut ta at ti io on ns s   
All  coding  genomic  changes  are  potentially
deleterious, the most straightforward ones being those
that are of nonsense type (that is, create a stop codon
or lead to a frameshift) or those that cause abnormal
splicing. In contrast, those mutations that lead to only
an amino acid substitution (missense mutations) cannot
be considered a priori pathogenic. Of all HNPCC
mutations so far seen in MLH1 and MSH2, 29% and
16% respectively are of missense type. In reality, many
missense mutations make interpretation an ordeal.
Furthermore, most studies to date have not included
analysis of MSH6 that undoubtedly causes HNPCC or
an HNPCC-like predisposition [55]. 
C Ca an nc ce er r   S Su ur rv ve ei il ll la an nc ce e
Cancer control is mandatory for sporadic as well
as hereditary forms of CRC. Importantly, one must
stratify  CRC  risk  status  and  then  meld  cancer
prevention strategies to the natural history of the
patient’s lifetime cancer risk [65]. 
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In  HNPCC,  annual  full  colonoscopy  initiated
between ages 20 and 25 is recommended for those
with strong clinical evidence and/or MLH1, MSH2, or
MSH6 germline mutations. Less frequent (every 3 years)
colonoscopy has been suggested in a consensus
statement, [66] but we believe this would lead to missed
CRCs,  given  the  phenomenon  of  accelerated
carcinogenesis [6, 34, 67, 68]. Table 2 shows our
surveillance recommendations for extra-colonic cancers
in  HNPCC.  For  example,  endometrial  screening
includes annual transvaginal ultrasound and pelvic
examination beginning at age 30. Transvaginal ovarian
ultrasound and CA-125 analysis may be helpful for
ovarian cancer surveillance in some patients; however,
their reduced sensitivity and specificity pose serious
limitations to these procedures. Screening for other
organ sites such as upper uro-epithelial tract and
stomach cancer (particularly in natives of Korea [69]
or Japan and/or when an excess of these extracolonic
cancers occur within a particular family) must also be
considered. Surgical prophylaxis (prophylactic subtotal
colectomy,  and  prophylactic  total  abdominal
hysterectomy and bilateral salpingo-oophorectomy is
presented as an option to selected patients [6, 43].
The efficacy of CRC surveillance in HNPCC was
evaluated in a controlled clinical trial extending over
15 years [70]. The incidence of CRC was compared
in two cohorts of at-risk members of 22 HNPCC
families. CRC developed in eight screened subjects
(6%), compared with 19 controls (16%; p = 0.014).
The CRC rate was reduced by 62%. All CRCs in the
screened  group  were  local,  causing  no  deaths,
compared with nine deaths caused by CRC in the
controls. It was concluded that CRC screening at three-
year intervals more than cuts in half the risk of CRC,
prevents CRC deaths, and decreases overall mortality
by about 65% in HNPCC families. The relatively high
incidence of CRC even in the screened subjects (albeit
without deaths) argues for shorter screening intervals,
e.g., one year.
S Su ur rv vi iv va al l   B Be en ne ef fi it t   i in n   H HN NP PC CC C
In spite of its ominous pathology features and the
proclivity to multiple primary CRCs, when compared for
age and stage with CRC in the general population, the
estimated death rate from CRC in HNPCC has been
reported to be, at most, only two-thirds of that in
sporadic CRC cases [71]. Interestingly, improved survival
was also one of the original defining features of the MTS
phenotype of HNPCC [6, 21-25, 27]. The reason(s) for
this improved survival remain elusive. It is possible that
immunologic factors may be responsible, as evidenced
by a peritumoral lymphocytic infiltration, the presence
of a Crohn’s-like reaction, and a marked excess of
tumor infiltrating lymphocytes (TILs) [72].
C Co on nc cl lu us si io on n
The diagnosis of HNPCC in certain clinical settings
may  prove  extremely  difficult,  given  the  many
obfuscating factors discussed in this review. The lack
of premonitory clinical signs, save the cutaneous
features of the Muir-Torre phenotype, [21-25, 27] to
aid in the diagnosis, is a particular obstacle to its
diagnosis. This is truly a pity, since the cancer preventive
opportunities, once a diagnosis of a high-risk individual
is established, truly abound. 
The bulk of the human genome has been mapped
[73]. This prodigious effort holds promise that more
cancer susceptibility genes will be found. Nevertheless,
as  we  continue  to  travel  with  anticipation  and
excitement into the brave new world of molecular
biology, we will need clinicians to utilize cancer genetics
as an important tool for cancer prevention. We will,
unfortunately, not be able to fulfill this objective in the
absence of well-thought-out descriptive family studies.
It is this very area that remains a blight to cancer
genetic progress, since it is still rare to examine a
medical chart and identify useful information about
that  patient’s  family  history  of  cancer  [74,  75].
However, on the positive side, a clinician who is armed
with knowledge about the genotypic and phenotypic
features of hereditary cancer syndromes, particularly
when coupled with a willingness to inquire about the
patient’s family history, will be in a most coveted
position to establish a diagnosis and then effectively
screen for those targeted organs that constitute a
hereditary cancer syndrome. 
Identifying HNPCC potentially saves lives through
early  cancer  detection  [70,  76].  This  effect  was
quantified in a study by Ramsey at al. [77] in a cost-
effectiveness analysis comparing standard care to a
process  including  application  of  the  Bethesda
guidelines, [30] followed by testing of the tumor for
MSI, then germline testing. In the case of mutation
carriers, life-long colorectal cancer surveillance was
indicated.  Results  showed  cost-effectiveness  of
surveillance up to $7,556 per life-year gained. Benefits
were greatest when immediate relatives (siblings and
children) of the index case were considered [77]. 
Reyes et al. [78] discuss selection strategies for
genetic testing of patients with HNPCC. They point out
that  molecular  testing  for  HNPCC  is  becoming
standard  care  and  that  it  is  cost-effective  when
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a  decision  analytic  model  for  evaluating  the
effectiveness and incremental cost-effectiveness of four
presently-used  testing  strategies  for  detection  of
HNPCC gene carriers, they initiated their model in the
population of CRC patients, measured the costs, the
number  of  gene  carriers  tested,  in  concert  with
incremental cost per gene carrier detected. Findings
disclosed that germline testing on only those CRC
probands who meet the Amsterdam criteria detected
the fewest number of gene carriers and had the lowest
cost. This was in contrast to MSI testing of all CRC
patients and families, which amounted to the highest
cost but detected the most gene carriers. Furthermore,
“... When cost effectiveness is considered, the mixed
strategy (MSH2 and MLH1 testing on those who meet
the Amsterdam criteria and germline testing for the
remainder who meet less stringent modified criteria
and are MSI-High) seems superior. The mixed strategy
detects 59.6 mutation carriers per 1,000 CRC cases
and costs much less than the test all strategy, which
has an incremental cost-effectiveness of $51,151. The
mixed strategy ... when compared to the Amsterdam
strategy, has a cost-effectiveness of only $6,441 per
gene carrier detected.“ These authors concluded that
it is not very effective to restrict testing to only those
individuals who meet the Amsterdam criteria, since
many gene carriers will be missed. On the other hand,
testing  all  CRC  patients  for  tumor  MSI-H,  while
effective, may be prohibitively expensive and therein a
mixed strategy is the more effective approach. 
This review of HNPCC has merely grazed the
surface of the proverbial iceberg when considering its
immense complexity. Issues to be solved for the
elucidation  and  control  of  HNPCC  include  the
following: 
1. What is its “complete“ tumor complement?
2. What are its chemotherapy and chemoprevention
implications?
3. Can we improve its surveillance/management
strategies?
4. Can  we  achieve  molecular-based  cancer
prevention for it?
5. What are its genotypic/phenotypic heterogeneity
implications?
6. What are its differential diagnostic implications?
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